ATE387186T1 - Neue zusammensetzungen von sildenafil-freier base - Google Patents
Neue zusammensetzungen von sildenafil-freier baseInfo
- Publication number
- ATE387186T1 ATE387186T1 AT04786037T AT04786037T ATE387186T1 AT E387186 T1 ATE387186 T1 AT E387186T1 AT 04786037 T AT04786037 T AT 04786037T AT 04786037 T AT04786037 T AT 04786037T AT E387186 T1 ATE387186 T1 AT E387186T1
- Authority
- AT
- Austria
- Prior art keywords
- free base
- sildenafil free
- new compositions
- sildenafil
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48910103P | 2003-07-23 | 2003-07-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE387186T1 true ATE387186T1 (de) | 2008-03-15 |
Family
ID=34135095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04786037T ATE387186T1 (de) | 2003-07-23 | 2004-07-23 | Neue zusammensetzungen von sildenafil-freier base |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20050042177A1 (de) |
| EP (1) | EP1658053B1 (de) |
| JP (1) | JP4860469B2 (de) |
| AT (1) | ATE387186T1 (de) |
| CA (1) | CA2533163A1 (de) |
| DE (1) | DE602004012117T2 (de) |
| ES (1) | ES2302035T3 (de) |
| WO (1) | WO2005013937A2 (de) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080102121A1 (en) * | 1998-11-02 | 2008-05-01 | Elan Pharma International Limited | Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone |
| CA2475092C (en) * | 2002-02-04 | 2012-05-01 | Baudax Bio, Inc. | Nanoparticulate compositions having lysozyme as a surface stabilizer |
| WO2004073729A1 (ja) | 2003-02-21 | 2004-09-02 | Translational Research Ltd. | 薬物の経鼻投与用組成物 |
| CA2519287A1 (en) | 2003-03-27 | 2004-10-14 | Bioactis Limited | Powder medicine applicator for nasal cavity |
| ATE387203T1 (de) | 2004-01-05 | 2008-03-15 | Teva Pharma | Prozesse zur herstellung von sildenafil-base und zitratsalz |
| AU2005249494A1 (en) | 2004-05-28 | 2005-12-15 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| WO2006016530A1 (ja) * | 2004-08-10 | 2006-02-16 | Translational Research, Ltd. | 速効性でかつ高い吸収性を可能とする経鼻投与用組成物 |
| CN101094659A (zh) * | 2004-12-31 | 2007-12-26 | 伊休蒂卡有限公司 | 纳米微粒组合物及其合成方法 |
| AU2012201630B8 (en) * | 2004-12-31 | 2014-03-06 | Iceutica Pty Ltd | NanoParticle Composition(s) and Method for Synthesis Thereof |
| US20090074796A1 (en) | 2005-01-07 | 2009-03-19 | The John Hopkins University | Pde5 inhibitor compositions and methods for immunotherapy |
| CA2598288A1 (en) * | 2005-03-03 | 2006-09-14 | Elan Pharma International Limited | Nanoparticulate compositions of heterocyclic amide derivatives |
| EP1871345B1 (de) | 2005-04-12 | 2012-08-01 | Elan Pharma International Limited | Nanopartikuläre erlotinib formulierungen |
| DE102005016981A1 (de) * | 2005-04-13 | 2006-10-19 | Bayer Healthcare Ag | Kombination zur Therapie bei benigner Prostatahyperplasie |
| KR20080008403A (ko) * | 2005-05-10 | 2008-01-23 | 엘란 파마 인터내셔널 리미티드 | 나노입자형 클로피도그렐 제제 |
| US20110064803A1 (en) * | 2005-05-10 | 2011-03-17 | Elan Pharma International Limited. | Nanoparticulate and controlled release compositions comprising vitamin k2 |
| US20100028439A1 (en) * | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
| BRPI0611075A2 (pt) * | 2005-06-03 | 2010-08-03 | Elan Pharma Int Ltd | formulações de acetaminofeno em nanopartìcula |
| ES2341996T3 (es) * | 2005-06-03 | 2010-06-30 | Elan Pharma International Limited | Formulaciones de mesilato de imatinib en forma de manoparticulas. |
| WO2006133045A1 (en) * | 2005-06-03 | 2006-12-14 | Elan Pharma International, Limited | Nanoparticulate benidipine compositions |
| EP1954253A4 (de) | 2005-06-08 | 2011-07-27 | Elan Pharma Int Ltd | Nanoteilchenförmige und kontrolliert freigesetzte zusammensetzungen mit cefditoren |
| EP1898882B1 (de) * | 2005-06-09 | 2009-10-28 | Elan Pharma International Limited | Nanopartikuläre ebastinformulierungen |
| CA2611741A1 (en) * | 2005-06-13 | 2006-12-28 | Elan Pharma International, Limited | Nanoparticulate clopidogrel and aspirin combination formulations |
| JP2008543862A (ja) * | 2005-06-15 | 2008-12-04 | エラン ファーマ インターナショナル リミテッド | ナノ粒子アゼルニジピン製剤 |
| JP2008546786A (ja) * | 2005-06-23 | 2008-12-25 | シェーリング コーポレイション | Ｐｄｅ５インヒビターの迅速吸収性経口処方物 |
| JP2008518041A (ja) * | 2005-08-29 | 2008-05-29 | テバ ファーマシューティカル インダストリーズ リミティド | 双峰性粒度分布を有する固体微粒子タダラフィル |
| US20070104792A1 (en) * | 2005-09-13 | 2007-05-10 | Elan Pharma International, Limited | Nanoparticulate tadalafil formulations |
| CA2622758A1 (en) * | 2005-09-15 | 2007-03-29 | Elan Pharma International, Limited | Nanoparticulate aripiprazole formulations |
| WO2007056457A2 (en) | 2005-11-09 | 2007-05-18 | Combinatorx, Incorporated | Methods, compositions, and kits for the treatment of medical conditions |
| US20080261995A1 (en) * | 2005-12-21 | 2008-10-23 | Pfizer Inc. | Pharmaceutical Combination of a Pde-5 Inhibitor and a 5-Alpha Reductase Inhibitor |
| DK1984344T3 (da) | 2005-12-29 | 2013-01-14 | Lexicon Pharmaceuticals Inc | Multicykliske aminosyrederivater og fremgangsmåder til anvendelse heraf |
| US7649098B2 (en) | 2006-02-24 | 2010-01-19 | Lexicon Pharmaceuticals, Inc. | Imidazole-based compounds, compositions comprising them and methods of their use |
| JP2009538927A (ja) | 2006-05-30 | 2009-11-12 | エラン ファーマ インターナショナル，リミティド | ナノ粒子状のポサコナゾール製剤 |
| DK2054042T3 (da) * | 2006-06-30 | 2020-08-03 | Iceutica Pty Ltd | Fremgangsmåder til fremstilling af biologisk aktive forbindelser i nanopartikelform |
| JP2009543797A (ja) * | 2006-07-10 | 2009-12-10 | エラン ファーマ インターナショナル，リミティド | ナノ粒子ソラフェニブ製剤 |
| KR20090031618A (ko) * | 2006-07-12 | 2009-03-26 | 엘란 코포레이션, 피엘씨 | 나노입자형 모다피닐 제제 |
| UA99270C2 (en) | 2006-12-12 | 2012-08-10 | Лексикон Фармасьютикалз, Инк. | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
| CN101668544B (zh) | 2006-12-26 | 2013-04-24 | 株式会社新日本科学 | 经鼻投用制剂 |
| WO2008091855A1 (en) * | 2007-01-22 | 2008-07-31 | Novavax, Inc. | Multi-phasic pharmaceutical formulations of poorly water-soluble drugs for reduced fed/fasted variability and improved oral bioavailability |
| KR100920106B1 (ko) * | 2007-11-14 | 2009-10-01 | 경북대학교 산학협력단 | 구연산 실데나필을 경피적으로 전달하기 위한 조절 약물전달체 및 이를 포함하는 경피 패치 |
| MX2010009848A (es) * | 2008-03-21 | 2010-09-30 | Elan Pharma Int Ltd | Composiciones para el suministro especifico en sitio de imatinib y metodos de uso. |
| KR101004205B1 (ko) | 2008-12-17 | 2010-12-24 | 동아제약주식회사 | 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물 |
| AU2010239081C1 (en) | 2009-04-24 | 2014-11-06 | Iceutica Pty Ltd | A novel formulation of indomethacin |
| US9101539B2 (en) * | 2009-05-15 | 2015-08-11 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal pharmaceutical compositions with improved pharmacokinetics |
| HUE032426T2 (en) | 2009-05-27 | 2017-09-28 | Alkermes Pharma Ireland Ltd | Inhibition of flake aggregation in nanoparticulate meloxicam formulations |
| SG177281A1 (en) | 2009-06-19 | 2012-02-28 | Nanoform Hungary Ltd | Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them |
| GB2472327B (en) * | 2009-07-31 | 2013-03-13 | Shin Nippon Biomedical Lab Ltd | Intranasal granisetron and nasal applicator |
| AU2010315190A1 (en) | 2009-11-05 | 2012-05-10 | Lexicon Pharmaceuticals, Inc. | Tryptophan hydroxylase inhibitors for the treatment of cancer |
| CA2789229A1 (en) | 2010-02-10 | 2011-08-18 | Lexicon Pharmaceuticals, Inc. | Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease |
| CA2802047C (en) * | 2010-06-07 | 2019-05-07 | Novadel Pharma Inc. | Oral spray formulations and methods for administration of sildenafil |
| HUP1000299A2 (hu) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra |
| CN102127182B (zh) * | 2010-12-23 | 2012-07-04 | 南京医科大学 | 用于检测pde-5抑制剂的磁性分子印记聚合物的制备方法 |
| MA34960B1 (fr) * | 2011-02-11 | 2014-03-01 | Ctc Bio Inc | Preparation de film contenant une base sans sidenafil et son procede |
| WO2013148978A1 (en) | 2012-03-30 | 2013-10-03 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for the treatment of necrotizing enterocolitis |
| FR2999086B1 (fr) * | 2012-12-10 | 2015-04-10 | Ethypharm Sa | Composition orale et/ou buccale sous forme de film fin d'un principe actif faiblement soluble, son procede de preparation et son utilisation |
| WO2014125343A1 (en) * | 2013-02-12 | 2014-08-21 | Alembic Pharmaceuticals Limited | Tadalafil tablet composition with reduced dose strength |
| WO2015010205A1 (en) | 2013-07-22 | 2015-01-29 | Université Du Québec À Chicoutimi | Use of plant extracts against herpes simplex virus |
| US20160317542A1 (en) | 2013-12-09 | 2016-11-03 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
| US9526734B2 (en) | 2014-06-09 | 2016-12-27 | Iceutica Pty Ltd. | Formulation of meloxicam |
| WO2017168174A1 (en) * | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
| KR101778688B1 (ko) | 2016-05-31 | 2017-09-15 | 한양대학교 에리카산학협력단 | 포스포다이에스터라제―5 억제제를 포함하는 약제학적 복합제제 |
| EP3576741A1 (de) | 2017-02-02 | 2019-12-11 | Dukebox SP. Z O.O. | Verfahren zur herstellung einer suspension von nanopartikeln aus tadalafil oder sildenafilcitrat |
| US11744967B2 (en) | 2017-09-26 | 2023-09-05 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal delivery devices |
| WO2019130052A1 (en) * | 2017-12-26 | 2019-07-04 | Ftf Pharma Private Limited | Liquid oral formulations for pde v inhibitors |
| GR1009643B (el) * | 2018-06-25 | 2019-11-12 | Arvo Μονοπροσωπη Ι.Κ.Ε. | Νεες συνθεσεις φαρμακευτικων σκευασματων σιλδεναφιλης μειωμενης περιεκτικοτητας σε δραστικη ουσια και νεες χρησεις τους |
| CN112972404A (zh) * | 2019-12-02 | 2021-06-18 | 北京兴源联合医药科技有限公司 | 一种西地那非冻干口腔崩解片及其制备方法 |
| CN112972405B (zh) * | 2019-12-02 | 2022-12-27 | 北京兴源联合医药科技有限公司 | 一种他达拉非冻干口腔崩解片及其制备方法 |
| PL3928772T3 (pl) | 2020-06-26 | 2024-10-07 | Algiax Pharmaceuticals Gmbh | Kompozycja nanocząstkowa |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| WO2022103638A1 (en) * | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Cannabinoids in the treatment of autism spectrum disorder |
| WO2023037394A1 (en) * | 2021-09-13 | 2023-03-16 | Amman Pharmaceutical Industries Company | A pharmaceutical composition of sildenafil and a formulation thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3315356A1 (de) * | 1982-04-30 | 1983-11-17 | Ono Pharmaceutical Co. Ltd., Osaka | Verwendung von prostaglandinanalogen |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| GT199900061A (es) * | 1998-05-15 | 2000-10-14 | Pfizer | Formulaciones farmaceuticas. |
| US6124461A (en) * | 1998-05-26 | 2000-09-26 | Saint Louis University, Health Services Center, Research Administration | Compounds, compositions, and methods for treating erectile dysfunction |
| US6428814B1 (en) * | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
| US6531114B1 (en) * | 1999-04-06 | 2003-03-11 | Wm. Wrigley Jr. Company | Sildenafil citrate chewing gum formulations and methods of using the same |
| US6270806B1 (en) * | 1999-03-03 | 2001-08-07 | Elan Pharma International Limited | Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions |
| US6267989B1 (en) * | 1999-03-08 | 2001-07-31 | Klan Pharma International Ltd. | Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions |
| US20010053780A1 (en) * | 1999-04-30 | 2001-12-20 | Whitaker John S. | Daily treatment for erectile dysfunction using a PDE5 inhibitor |
| US7919119B2 (en) * | 1999-05-27 | 2011-04-05 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| TW200400821A (en) * | 1999-11-02 | 2004-01-16 | Pfizer | Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient |
| CA2391968A1 (en) * | 1999-11-18 | 2001-05-25 | Natco Pharma Limited | An improved pharmaceutical composition for treating male erectile dysfunction |
| DE10010612A1 (de) * | 2000-03-03 | 2001-09-27 | Merck Patent Gmbh | Verwendung von PDE V-Inhibitoren |
| EP1289526A4 (de) * | 2000-05-30 | 2005-03-16 | Merck & Co Inc | Agoniste des melanocortin-rezeptors |
| CA2417736A1 (en) * | 2000-07-19 | 2002-01-24 | Lavipharm Laboratories, Inc. | Sildenafil citrate solid dispersions having high water solubility |
| US6548508B2 (en) * | 2000-10-20 | 2003-04-15 | Pfizer, Inc. | Use of PDE V inhibitors for improved fecundity in mammals |
| CA2446904A1 (en) * | 2001-05-24 | 2003-04-03 | Alexza Pharmaceuticals, Inc. | Delivery of drug esters through an inhalation route |
| WO2002094219A2 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of erectile dysfunction drugs through an inhalation route |
| US7766013B2 (en) * | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
| US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
| WO2004006959A1 (en) * | 2002-07-16 | 2004-01-22 | Elan Pharma International, Ltd | Liquid dosage compositions of stable nanoparticulate active agents |
| GB0219516D0 (en) * | 2002-08-21 | 2002-10-02 | Phoqus Ltd | Fast dissolving and taste masked oral dosage form comprising sildenafil |
-
2004
- 2004-07-21 US US10/895,405 patent/US20050042177A1/en not_active Abandoned
- 2004-07-23 JP JP2006521069A patent/JP4860469B2/ja not_active Expired - Fee Related
- 2004-07-23 DE DE602004012117T patent/DE602004012117T2/de not_active Expired - Lifetime
- 2004-07-23 CA CA002533163A patent/CA2533163A1/en not_active Abandoned
- 2004-07-23 AT AT04786037T patent/ATE387186T1/de not_active IP Right Cessation
- 2004-07-23 EP EP04786037A patent/EP1658053B1/de not_active Expired - Lifetime
- 2004-07-23 WO PCT/US2004/019106 patent/WO2005013937A2/en not_active Ceased
- 2004-07-23 ES ES04786037T patent/ES2302035T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US20050042177A1 (en) | 2005-02-24 |
| ES2302035T3 (es) | 2008-07-01 |
| JP2006528176A (ja) | 2006-12-14 |
| JP4860469B2 (ja) | 2012-01-25 |
| CA2533163A1 (en) | 2005-02-17 |
| WO2005013937A2 (en) | 2005-02-17 |
| EP1658053A2 (de) | 2006-05-24 |
| DE602004012117T2 (de) | 2009-02-26 |
| WO2005013937A3 (en) | 2005-06-16 |
| DE602004012117D1 (de) | 2008-04-10 |
| EP1658053B1 (de) | 2008-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE387186T1 (de) | Neue zusammensetzungen von sildenafil-freier base | |
| ATE415946T1 (de) | Neue metaxalon-zusammensetzungen | |
| ATE419835T1 (de) | Nystatin-nanopartikelzusammensetzungen | |
| CY1113036T1 (el) | Φαρμακοτεχνικες μορφες νανοσωματιδιων μεγεστρολης | |
| WO2005002542A3 (en) | Nanoparticulate meloxican formulations | |
| SG161203A1 (en) | Nanoparticulate tacrolimus formulations | |
| EA200401556A1 (ru) | Препараты на основе наночастиц фибрата | |
| ATE343376T1 (de) | Nanopartikelzusammensetzungen von angiogeneseinhibitoren | |
| EA200701997A1 (ru) | Композиция из наночастиц бисфосфоната | |
| ATE385777T1 (de) | Nanopartikelzusammensetzungen von mitogen- aktivierten protein (map) kinase inhibitoren | |
| MXPA05007635A (es) | Composicion para la limpieza personal que contiene particulas de forma irregular y particulas esfericas. | |
| ATE395042T1 (de) | Darreichungsformen welche mikropartikel und treibgas enthalten | |
| UA81624C2 (ru) | Тризамещённые гетероарилы и способ их получения и применение | |
| BR0317444A (pt) | Partìculas de percarbonato de sódio com melhor estabilidade de estocagem | |
| EA200701107A1 (ru) | Твердая фармацевтическая композиция, содержащая валсартан | |
| DE60310936D1 (de) | Riechstoffzusammensetzung | |
| NO20080403L (no) | Nanopartikulaere megestrolformuleringer | |
| ATE332120T1 (de) | Shampoo mit hohlen teilchen | |
| ATE359765T1 (de) | Verringerung der teilchengrösse von bioaktiven verbindungen | |
| PT1453380E (pt) | Composicoes contendo sacarido e silica hidrofobica | |
| TH62485A (th) | องค์ประกอบของผลิตภัณฑ์ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |